Page last updated: 2024-08-23

amikacin and flomoxef

amikacin has been researched along with flomoxef in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Kobayashi, J; Kouda, M; Kumagai, I; Matsuzaki, H; Sugai, R1
Cheng, KC; Chuang, YC; Huang, GC; Wu, LT; Yu, WL1
Da Costa, RMA; Darlow, CA; Das, S; Ellis, S; Farrington, N; Franceschi, F; Hope, W; Jagota, B; Jimenez-Valverde, A; Johnson, A; Kolamunnage-Dona, R; McEntee, L; Neely, M; Piddock, L; Sharland, M; Unsworth, J1

Other Studies

3 other study(ies) available for amikacin and flomoxef

ArticleYear
[Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. II. In vitro combined effects of sulbactam/cefoperazone with imipenem/cilastatin, cefuzonam, flomoxef, amikacin or tobramycin].
    The Japanese journal of antibiotics, 1991, Volume: 44, Issue:2

    Topics: Amikacin; Anti-Bacterial Agents; Bacteria; Cefoperazone; Ceftizoxime; Cephalosporins; Cilastatin; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Sulbactam; Tobramycin

1991
Clinical experiences of the infections caused by extended-spectrum beta-lactamase-producing Serratia marcescens at a medical center in Taiwan.
    Japanese journal of infectious diseases, 2006, Volume: 59, Issue:3

    Topics: Amikacin; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Taiwan

2006
Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings.
    The Journal of antimicrobial chemotherapy, 2022, 11-28, Volume: 77, Issue:12

    Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Delivery of Health Care; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Neonatal Sepsis

2022